Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Anti-angiogenesis drugs in lung cancer RESPIROLOGY Lee, S., Baas, P., Wakelee, H. 2010; 15 (3): 387–92

Abstract

In the last years much attention has been given to the implementation of the so-called targeted drugs. One of the targets of tumours is the vasculature and this has led to the development of anti-angiogenic drugs. In lung cancer the use of these drugs has resulted in both positive and negative studies. In this paper the pros and cons are presented. We hope that this information will help the physician in making a proper treatment choice.

View details for DOI 10.1111/j.1440-1843.2010.01715.x

View details for Web of Science ID 000276036400003

View details for PubMedID 20337999